BeyondSpring to Present Phase 2 Plinabulin Docetaxel Pembrolizumab Data in 47 NSCLC Patients
BeyondSpring will present Phase 2 Study 303 at the ASCO Annual Meeting on May 31, detailing the triple combination of plinabulin, docetaxel and pembrolizumab in 47 metastatic NSCLC patients previously treated with PD-1/PD-L1 inhibitors. The investigator-initiated trial, supported by Merck, evaluates ORR, PFS, OS and safety.
1. Poster Presentation Details
BeyondSpring’s poster on Study 303 will be presented on Sunday, May 31, 2026, from 9:00 a.m. to 12:00 p.m. CDT at McCormick Place in Chicago. It appears in the Lung Cancer – Non-Small Cell Metastatic session under abstract number 8567 and poster board 357.
2. Study 303 Overview
Study 303 is an open-label, single-arm Phase 2 trial enrolling 47 patients with second- or third-line metastatic NSCLC who progressed on PD-1/PD-L1 inhibitors. Patients receive plinabulin 30 mg/m2, docetaxel 75 mg/m2 and pembrolizumab 200 mg IV every three weeks, with primary endpoint investigator-assessed ORR (RECIST 1.1) and secondary endpoints PFS, OS, DoR and safety.
3. Funding and Trial Design
The trial is conducted at Peking Union Medical College Hospital with Dr. Mengzhao Wang as principal investigator and is funded by Merck’s Investigator Studies Program alongside BeyondSpring, which provides study drug and financial support. It is registered under NCT05599789.